Zebra Analytix Receives NIH Grant for Rapid Breath Detection of Hazardous Substance Exposure

FAYETTEVILLE, AR - Zebra Analytix, Inc.—a VIC Technology Venture Development portfolio company—announced today that it has been awarded a National Institutes of Health (NIH) Small Business Innovation Research (SBIR)...

VIC Foundry, Inc. Receives NIH RADx Funding for Development of an At-home Molecular Diagnostic Test for COVID-19

VIC Foundry, in collaboration with Sandia National Laboratories, is developing a self-contained isothermal nucleic acid amplification test to address an unmet need for at-home testing of COVID-19 infection. This...

VIC 2020 Annual Report Executive Summary

Despite the challenges 2020 brought, we saw promising progress for VIC and our portfolio companies. Click Here to download the Annual Report Executive Summary or view it below.

VIC Fellows Spotlight: Kirt Gill, MD

The VIC Fellows Program provides an opportunity for individuals with relevant expertise and interest to learn how to identify and evaluate promising innovation from global sources. We are pleased to highlight the...

Diabeloop SA and SFC Fluidics Announce Development Agreement

SFC Fluidics Inc., developer of an Alternate Controller Enabled (ACE) insulin delivery pod and Diabeloop, pioneer in therapeutic artificial intelligence, are partnering to integrate the SFC ACE insulin pod into...

CardioWise Receives US FDA 510(k) Clearance for Heart Function Analysis Software

CardioWise, Inc., is pleased to announce Clearance of its 510(k) application by the US Food and Drug Administration (FDA) for its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones...

A Letter from our CEO

When I wrote my last “letter from the CEO” in January 2020, I did not foresee the tumultuous year ahead. For so many, it’s been a tragic and difficult year on a personal level. We have all been impacted by the pandemic...

Neurexis Therapeutics Works to Solve an Unmet Healthcare Need

CBSA President & CEO, Jennifer Jones Paton, asked Michael Artinger, PhD, Neurexis’ Chief Executive Officer, CBSA’s Key Questions for Life Sciences Innovators.

VIC Investor Network Introduces a Secondary Market for Members

Provides VIN Members Early Liquidity Options FAYETTEVILLE, AR. DECEMBER 14, 2020- The VIC Investor Network (“VIN”) makes investments into companies based on technologies that can have substantial impact on human health...

SFC Fluidics, Inc. Receives FDA Breakthrough Device Designation

FDA’s BDD program targets novel devices with the potential to provide patients with a more effective treatment for life-threatening or irreversibly debilitating diseases. SFC’s insulin pod promises to substantially...

FEATURED RESOURCES

Updates
VIC Tech Announces New Class of Fellows
Insight
Our Life Science and Healthcare Future
White Paper
Portfolio Diversification in Times of Market Volatility
Interview
Inside the Office of Technology Commercialization at the University of Kentucky with Holly Clark, PhD, Senior Commercialization Manager
Insight
Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio
White Paper
Investing in Medical Devices & Diagnostics – Industry Trends and Investor Activity
News
Nob Hill Therapeutics Secures Series A Funding to Advance Breakthrough Respiratory Technologies
Interview
VIC Fellows Spotlight: Matthew Leming, PhD
From The Corner Office
From the Corner Office: Zebra Analytix